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Abstract 
Background: Breast cancer is the most frequent cancer in women in the western 
world. With breast cancer now affecting one in ten women, it is important to know 
how this disease burden is shared among women.  
Aims: This study was undertaken to determine the survival rate of breast cancer in 
southern Iran. 
Methods and Material: From December 2001 to December 2006, among 8000 
hospital-based registered cancer cases in southern Iran, 863 individuals with breast 
cancer entered our study. One, 5, 10 and 15 year-survival rates were estimated by 
Kaplan Meier function. 
Results: Mean age at the time of diagnosis of breast cancer was 46.3 years 
(SD=11.5). About 25.4% had a previous family history of cancer in their first and 
13.8% in their second degree relatives. About 92.5%, 71.3% and 41.4% of breast 
cancer cases underwent surgery, radiotherapy and chemotherapy, respectively. 
Nearly 11.7% of patients had a history of exposure to chemical materials. About 
32.3% were passive and 19.2% were active smokers. Totally, one, 5, 10 and 15 
year-survival rates were 97%, 67%, 45% and 25%, respectively. The survival rate 
had a significant negative correlation with age at the time of diagnosis. 
Conclusions: The survival rate of women with breast cancer in southern Iran seems 
to be identical to other parts of the country and stands between western and 
eastern European countries.  
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Introduction 
About Breast cancer is the most common 
malignancy in women, but incidence varies more than 
10-fold worldwide [1]. Due to earlier detection and 
improved treatment methods, the mortality rate of 
breast cancer has decreased largely [2]. However, 
breast cancer is still the most prevalent diagnosed 
cancer in women with a high mortality. About 40,410 
women were reported to die of breast cancer in the 
United States in 2005 [3]. Western European and 
North American populations are at highest risk, with 
a lifetime risk of 8-10% up to the age of 74 years 
(1 in 12 to 1 in 10 women), while the lowest risks 
(around 1%) generally exists in Asian populations 
[4]. In addition to cancer stage at the time of 
diagnosis and treatment, [5–6] several other factors 
may explain the variability in breast cancer survival. 
Wide variations in breast cancer survival exist 
between countries [7-8]. 
As there were no data available in relation to 
breast cancer survival in our area, we sought to 
determine the survival rate in Fars Province, southern 
Iran. 
Subjects and Methods 
Fars Hospital-based Cancer Registry affiliated to 
Shiraz University of Medical Sciences was founded in 
1971 in Shiraz, collecting medical and demographic 
information from various medical sources throughout 
Fars in southern Iran. The records kept in the medical 
archives were scrutinized and the personnel 
interviewed the patients face to face for all 
information. The collected information included age, 
occupation, date of incidence, primary site, histology, 
response to therapy, survival status, follow up 
information, family history and socioeconomic status. 
The primary site and morphology data were coded 
using the ICD-O [9,10]. Our materials included all 
malignancies diagnosed microscopically by biopsy, 
resection or discovered at necropsy. 
A historical prospective study was done, during a 
period of 5 years, from December 2001 to 
December 2006, and the cancer registry team 
actively collected and compiled data for a period of 
17 years from 1989 to 2006 from 4 hospitals of 
Shiraz University of Medical Sciences. To date, over 
8000 cases of malignant neoplasm have been 
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Table 1: Mean and median survival time (year) in relation to age at the time of breast cancer diagnosis, 
southern Iran.
95% Confidence Interval 95% Confidence Interval P value* 
Mean Median 
Lower Bound Upper Bound Lower Bound Upper Bound
Age at time <=50 11.35 9.91 12.76 9.34 6.96 11.73 0.01 
of diagnosis >50 8.56 7.06 10.05 8.01 4.97 11.06
Totally 10.36 9.25 11.48 8.62 7.13 10.11
*P value is due to mean and median
Heydari ST et al.
registered, 1028 cases were breast cancer, but 863 
cases were enrolled because of the presence of 
follow-ups in their files while 165 cases were 
excluded from the study (14 males and 151 cases 
without any follow-ups) due to the telephone and 
address changes. The missing data is assumed as 
random. After at least 6 months, the registered 
patients were followed and their files were 
completed. Their follow up was based on patients' 
telephone and medical files. SPSS (Chicago, IL, 
version 13) was used for statistical analyses. We 
used Kaplan Meier for determined survival rate and 
Log-Rank test for comparison. A P-value less than 
0.05 was considered significant. 
Results 
Mean age at the time of diagnosis was 46.5 years 
(SD=11.7, range=19-86 years) while 78 cases were 
single, 713 married and 86 divorced. 223 (25.4%) 
had a previous family history of cancer in their first 
and 121 cases (13.8%) in their second degree 
relatives. 811 (92.5%), 625 (71.3%) and 363 
(41.4%) individuals had undergone surgery, 
radiotherapy and chemotherapy for breast cancer. 
103 patients (11.7%) had a history of exposure to 
chemical materials and 283 (32.3%) were passive 
smokers, while 168 (19.2%) were active cigarette 
smokers. One, 5, 10 and 15 year-survival rates were 
97% (95% confidence interval = 96% to 98%), 
67% (95% confidence interval = 63% to 72%), 
45% (95% confidence interval = 38% to 51%) and 
25% (95% confidence interval = 16% to34%), 
respectively (Fig 1). Survival rate was correlated 
with age at the time of diagnosis and was correlated 
with breast cancer survival (P value=0.01) (Fig 2). 
Median and mean survival times were 8.62 (95% 
confidence interval = 7.13 to 10.11) and 10.36 
(95% confidence interval = 9.25 to 11.48) (Table 1). 
Discussions 
Breast cancer is considered to be the second most 
commonly diagnosed cancer worldwide [11]. It ranks 
the second most common cancer among Iranian 
women too [12,13]. The median disease-free survival 
for patients with breast cancer has been reported to 
be 49.6 months by Gohari et al. [14,15] Our median 
survival time was 64 months. The overall relative 5-
year survival rate was found to be 75%. Vahidian 
and Montazeri [16] showed a figure of 62% in 
Iranian breast cancer patients to stand between 
western and eastern European countries. So, early 
detection and better management using standard 
guidelines might contribute considerably to the 
improvement of survival in women with breast cancer. 
Mousavi et al. [13] reported a similar 75% five year 
survival rate in Iran. In Mashhad, North-east of Iran, 
a 5 year overall survival rate of 47.7% has been 
reported [17] showing that younger age had a 
significant adverse effect on survival rate. Ueno et 
al. [18] showed 5-year survival rates of 80.3% and 
67.5% during two periods which was associated with 
age at the time of diagnosis. Taylor et al. [19] 
noticed a 76 percent 5-year survival in New South 
Wales. In Western Australia, Clayforth et al. [20] 
reported a 79% survival in western Sydney. The age 
at the time of diagnosis in Western Australia ranged 
from 22 to 92 years (mean=56.7 years) and 31% 
of cases were younger than 50 years of age which is 
at least 10 years older than Iran [20]. Its association 
with prognostic factors such as age, cancer stage and 
effectiveness of treatment has been previously shown 
[21-23] but the effect of age on breast cancer 
survival is still a matter of controversy. Several 
studies have shown that survival among young 
women is worse than that among older women 
[24,25]. Others have shown that age is not 
correlated with disease-free or overall survival after 
adjustment for other prognostic variables [26-28]. 
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Figure 1: Survival curve of breast cancer in southern Iran. Figure 2: Survival curve of breast cancer in 
relation to age at the time of diagnosis in 
Some have even reported that young patients have 
a better survival [29]. According to the risk 
categories of the St. Gallen International Expert 
Consensus Meeting, age is a risk factor 
(www.oncoconferences.ch/2005/home/home.htm). 
The mean age of the patients at the time of 
diagnosis of breast cancer was 46.5±11.7 (19-86 
years old in our study. Harirchi et al. [30] have 
mentioned mean ages of 47.1 and 48.8 years for 
women with breast cancer which are close to our 
figures. Mousavi et al. [13] reported a mean age of 
51.3±12.5 years. Our findings are consistent with 
studies showing that being young at the time of 
diagnosis is a prognostic factor for survival [31,32]. 
Therefore, age at the time of diagnosis should be 
considered as an important factor for making 
decisions on adjuvant therapy, irrespective of nodal 
status, as breast cancer affects women in Iran at 
least one decade sooner than their counterparts in 
developed countries [33,34]. 
A comprehensive national cancer program 
including promotion of awareness, early detection, 
encouraging women for breast self-examination, 
treatment and palliative cares and participation in 
screening campaigns are important to decrease the 
burden of breast cancer in women ≤50 years of age 
in our area. This strategy is highly suggested to 
policy makers and health authorities. The survival 
rate of women with breast cancer in southern Iran 
seems to be similar to other parts of the country and 
stands between western and eastern European 
countries. 
southern Iran. 
The limitation of this study was that we missed 
some patients, because their address or telephone 
had changed since our only source of data was the 
recode files of the Cancer Registry of Shiraz Medical 
University. 
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